Novo led the sustainable materials producer’s series C round, three years after a round backed by investors including Ginkgo Bioworks.

US-based bioengineering technology provider Genomatica has closed a $118m series C round led by pharmaceutical firm Novo. Casdin Capital, Nicholas Investment Partners, Tenere Capital, Tharsis Capital and Viking Global Investors filled out the participants in the round. Founded in 2000, Genomatica produces sustainable chemicals which leverage plant and waste-derived raw materials to replace traditional materials…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.